Thursday 15 October 2026
Export CGEN’s income statement to Excel — free account
Compugen Ltd.
CGEN Healthcare Biotechnology
Compugen Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $72.8 million, up 161.1% from fiscal 2024. In the quarter to June 2026, revenue grew 107.0%, EPS grew 12.5% and free cash flow fell 155.4%, each against the same quarter a year earlier.
2.08
0.08
+4.00%
Follow CGEN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
7 | — | — | — |
+8 more TTM periods Free account |
| 47.85% | 0.00% | 42.00% | 0.00% | ||
| 23.86% | 26.68% | 26.03% | (24.95%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
32.75% | 30.08% | 28.02% | (39.79%) | |
Average Days of Receivables |
20.27 | 11.75 | 11.95 | 149.74 | |
Free Cash Flow per Share |
0.42 | 0.00 | 1.09 | 0.00 | |
Free Cash Flow |
40.04 | — | 101.69 | — | |
Capital Expenditures |
(0.69) | — | (0.69) | — | |
| Other line items | |||||
Cash ROIC |
18.71% | 0.00% | 40.94% | 0.00% | |
Accounts Receivable Turnover |
22.80 | 26.49 | 28.40 | 2.79 | |
Accounts Payable Turnover |
4.86 | 3.54 | 3.16 | 0.00 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
81.06 | 106.28 | 92.84 | 0.00 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
33.23% | 32.92% | 31.28% | 335.00% | |
Selling, General and Administrative Expense of Revenue |
12.72% | 12.88% | 12.96% | 138.90% | |
Share Based Compensation of Revenue |
8.73% | 0.00% | 10.34% | 0.00% | |
Operating CF/Net income |
1.16 | 0.00 | 2.90 | 0.00 | |
Depreciation/Fixed assets |
(1.05) | 0.00 | (0.92) | 0.00 | |
Capex/Depreciation |
0.95 | — | 1.10 | — | |
Revenue per Share |
0.78 | 0.77 | 0.78 | 0.07 | |
Operating CF per Share |
0.43 | 0.00 | 1.10 | 0.00 | |
Capex per Share |
(0.01) | 0.00 | (0.01) | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.01 | 0.00 |
Columns are period end dates